323204-96-2Relevant academic research and scientific papers
INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
-
, (2021/12/28)
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
-
, (2021/12/30)
Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
-
, (2020/12/07)
Provided herein are inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES
-
, (2012/08/08)
The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS
-
, (2012/08/08)
The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.
PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
-
, (2011/04/14)
The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.
HETEROARYL COMPOUNDS AS KINASE INHIBITORS
-
, (2011/04/14)
The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor
Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors
Stevens, Kirk L.,Alligood, Krystal J.,Alberti, Jennifer G. Badiang,Caferro, Thomas R.,Chamberlain, Stanley D.,Dickerson, Scott H.,Dickson, Hamilton D.,Emerson, Holly K.,Griffin, Robert J.,Hubbard, Robert D.,Keith, Barry R.,Mullin, Robert J.,Petrov, Kimberly G.,Gerding, Roseanne M.,Reno, Michael J.,Rheault, Tara R.,Rusnak, David W.,Sammond, Douglas M.,Smith, Stephon C.,Uehling, David E.,Waterson, Alex G.,Wood, Edgar R.
scheme or table, p. 21 - 26 (2009/04/10)
A novel class of pyrrolidinyl-acetyleneic thieno[3,2-d]pyrimidines has been identified which potently inhibit the EGFR and ErbB-2 receptor tyrosine kinases. Synthetic modifications of the pyrrolidine carbamate moiety result in a range of effects on enzyme and cellular potency. In addition, the impact of the absolute stereochemical configuration on cellular potency and oral mouse pharmacokinetics is described.
Pyrrolidine PNA: A Novel Conformationally Restricted PNA Analogue
Pueschi, Ask,Tedeschi, Tullia,Nielsen, Peter E.
, p. 4161 - 4164 (2007/10/03)
A new conformationally restricted PNA adenine monomer has been synthesized in 13 steps from cis-4-hydroxy-D-proline. A fully modified adenine decamer displayed improved binding affinity toward complementary DNA and RNA oligonucleotides as compared to that of the parent PNA adenine decamer.
